JP5948597B2 - 純粋なエルロチニブ - Google Patents

純粋なエルロチニブ Download PDF

Info

Publication number
JP5948597B2
JP5948597B2 JP2013520221A JP2013520221A JP5948597B2 JP 5948597 B2 JP5948597 B2 JP 5948597B2 JP 2013520221 A JP2013520221 A JP 2013520221A JP 2013520221 A JP2013520221 A JP 2013520221A JP 5948597 B2 JP5948597 B2 JP 5948597B2
Authority
JP
Japan
Prior art keywords
erlotinib
solvent
base
salt
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013520221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531058A5 (https=
JP2013531058A (ja
Inventor
ヴィナヤック ゴヴィンド ゴア，
ヴィナヤック ゴヴィンド ゴア，
アニルクマー トライパティ，
アニルクマー トライパティ，
マダーヴ ジャダーヴ，
マダーヴ ジャダーヴ，
Original Assignee
ジェネリクス・［ユーケー］・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・［ユーケー］・リミテッド filed Critical ジェネリクス・［ユーケー］・リミテッド
Publication of JP2013531058A publication Critical patent/JP2013531058A/ja
Publication of JP2013531058A5 publication Critical patent/JP2013531058A5/ja
Application granted granted Critical
Publication of JP5948597B2 publication Critical patent/JP5948597B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013520221A 2010-07-23 2011-07-22 純粋なエルロチニブ Expired - Fee Related JP5948597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2112MU2010 2010-07-23
IN2112/MUM/2010 2010-07-23
PCT/GB2011/051394 WO2012028861A1 (en) 2010-07-23 2011-07-22 Pure erlotinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016093409A Division JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Publications (3)

Publication Number Publication Date
JP2013531058A JP2013531058A (ja) 2013-08-01
JP2013531058A5 JP2013531058A5 (https=) 2014-09-11
JP5948597B2 true JP5948597B2 (ja) 2016-07-06

Family

ID=44514823

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013520221A Expired - Fee Related JP5948597B2 (ja) 2010-07-23 2011-07-22 純粋なエルロチニブ
JP2016093409A Expired - Fee Related JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016093409A Expired - Fee Related JP6374436B2 (ja) 2010-07-23 2016-05-06 純粋なエルロチニブ

Country Status (8)

Country Link
US (2) US8952022B2 (https=)
EP (1) EP2595629A1 (https=)
JP (2) JP5948597B2 (https=)
CN (1) CN103124557A (https=)
AU (1) AU2011298167B2 (https=)
CA (1) CA2806273A1 (https=)
NZ (2) NZ628796A (https=)
WO (1) WO2012028861A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628796A (en) * 2010-07-23 2016-02-26 Generics Uk Ltd Pure erlotinib
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014023027A1 (zh) * 2012-08-10 2014-02-13 上海创诺医药集团有限公司 盐酸埃罗替尼多晶型物及其制备方法
WO2014118112A1 (en) * 2013-01-29 2014-08-07 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN104072427B (zh) * 2013-03-29 2019-05-28 江苏豪森药业集团有限公司 盐酸厄洛替尼晶型的制备方法
WO2020165672A1 (en) 2019-02-15 2020-08-20 Shivalik Rasayan Limited Process for preparation of highly pure fingolimod hydrochloride

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707453A (es) * 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7625911B2 (en) 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
US7960545B2 (en) 2005-11-23 2011-06-14 Natco Pharma Limited Process for the prepartion of erlotinib
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
US8349855B2 (en) 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
NZ579997A (en) 2007-04-04 2012-08-31 Cipla Ltd PROCESS FOR PREPARATION OF N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
WO2009002538A2 (en) 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) * 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
WO2009024989A2 (en) 2007-08-17 2009-02-26 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090131665A1 (en) 2007-08-23 2009-05-21 Ales Gavenda Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
WO2010040212A1 (en) 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
NZ628796A (en) * 2010-07-23 2016-02-26 Generics Uk Ltd Pure erlotinib

Also Published As

Publication number Publication date
AU2011298167A1 (en) 2013-02-07
AU2011298167B2 (en) 2015-11-26
JP6374436B2 (ja) 2018-08-15
US8952022B2 (en) 2015-02-10
CN103124557A (zh) 2013-05-29
US20130210842A1 (en) 2013-08-15
WO2012028861A1 (en) 2012-03-08
EP2595629A1 (en) 2013-05-29
JP2013531058A (ja) 2013-08-01
US20150111847A1 (en) 2015-04-23
AU2011298167A8 (en) 2013-02-21
CA2806273A1 (en) 2012-03-08
US9340515B2 (en) 2016-05-17
NZ628796A (en) 2016-02-26
NZ606042A (en) 2015-05-29
JP2016196463A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
JP6374436B2 (ja) 純粋なエルロチニブ
EP2970123B2 (en) Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
MXPA06004076A (es) Proceso para la preparacion de compuestos de aminocrotonilo.
US20200369652A1 (en) Processes for preparation of lifitegrast and intermediates thereof
EP3535264A2 (en) Process for the preparation of venetoclax
JP2020528064A (ja) Ｌｆａ−１拮抗薬リフィテグラストを調製および精製するためのプロセス
KR20130038258A (ko) 삭사글립틴 중간체, 삭사글립틴 다형 및 이들의 제조 방법
CN110891947B (zh) 制备艾乐替尼或其药学上可接受的盐的方法
US20190241511A1 (en) Polymorphic forms of belinostat and processes for preparation thereof
WO2020141562A1 (en) Novel crystalline forms and process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
CN103724360B (zh) 吡啶(或苯)并噻唑化合物及其中间体、制备方法和应用
CN113583003A (zh) 一种伐地那非类似物及其合成方法和应用
AU2013204155A1 (en) Pure erlotinib
JP7842890B2 (ja) ４－［５－［ビス（２－クロロエチル）アミノ］－１－メチル－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル］酪酸アルキルエステル及びホルミル化誘導体の調製方法
JP7416842B2 (ja) 縮合多環式化合物の調製方法
CN101423524B (zh) 二谷氨酸酯衍生物及其在培美曲塞制备中的应用
CN113461694A (zh) 一种伐地那非类似物及其合成方法和应用
WO2018130942A1 (en) A process for the preparation of phenoxybenzamine
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160506

R150 Certificate of patent or registration of utility model

Ref document number: 5948597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees